Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Improving availability of ImmunoPET via automation of radio-synthesis and quality control of antibody-based HIV imaging PET tracers on a single platform.

Award Number: R44AI162202
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 01/15/2024
PERIOD OF PERFORMANCE END DATE: 12/31/2026

Group Awards By:

View Award Description

Improving availability of ImmunoPET via automation of radio-synthesis and quality control of antibody-based HIV imaging PET tracers on a single platform. - ImmunoPET Imaging allows visualization of biological processes in the body via radiolabeled monoclonal antibodies (mAb’s) with Positron Emission Tomography (PET). ImmunoPET has proven to be a groundbreaking innovation yielding actionable medical information that is not otherwise obtainable in many disease areas. However, ImmunoPET imaging is only available at select academic centers limited by complexity of production of short-lived Zr-89-radiolabeled antibodies., which prevents access of ImmunoPET to the majority of patient population and to clinical trial utilization. To address this barrier, Trace-Ability will develop Tracer-ONE – compact and affordable automation of the entire [Zr- 89]mAb production procedure including radio-labeling, QC and immunoassay with results available before the PET scan. Production staff will need only to install a kit, add the radionuclide, initiate the process and return to collect the product along with QC report. Such solution will enable any facility with limited staff and budget to start producing ImmunoPET tracers in a scalable, standardized, safe and GMP-compliant manner. Key new capabilities needed for Tracer-ONE have been demonstrated in Phase I including radiolabeling, immunoreactivity assay and most QC tests. Phase II is designed to deliver a fully-functional system suitable for cGMP production of a variety ImmunoPET tracers for clinical use. To maximize the immediate impacts of the project, we chose the HIV application of ImmunoPET, currently limited to a single location in the US. To demonstrate the scalability of Tracer-ONE, we will sequentially enable two HIV ImmunoPET tracers starting with [Zr-89]VRC01. Specific Aim 1 Develop fully automated [Zr-89]VRC01 radio-synthesis starting with [Zr-89]oxalate and a disposable kit and yielding [Zr-89]VRC01 that meets all requirements for clinical use. Specific Aim 2 Develop fully automated [Zr- 89]VRC01 quality control including immunoreactivity. The deliverable of this aim is to design a disposable kit and corresponding protocol to enable all measurements required prior to clinical use of [Zr-89]VRC01. Specific Aim 3 Optimize Tracer-ONE for fully automated production of [Zr-89]VRC01 for clinical use. The ultimate deliverable of this aim is acceptance of the system’s performance by UCSF quality and regulatory groups. Specific Aim 4 Demonstrate efficient expansion of established Tracer-ONE capabilities to another HIV ImmunoPET tracer. The deliverable of this aim is a fully automated radiosynthesis and QC process on Tracer-ONE qualified for a second HIV tracer at UCSF and meeting the same acceptance criteria as [Zr-89]VRC01. The outcome of the project is principal enablement of a capability that does not exist today – routine ImmunoPET tracer production across a diverse range of products leading to broad availability of ImmunoPET imaging to American patients in AIDS, cancer, arthritis and other disease areas. In additional to diagnostic value, broad availability of ImmunoPET will increase the effectiveness of clinical trials and availability of new therapies and the percentage of patients that respond to therapies.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $1,000,000 )
2025	2025	TRACE-ABILITY INC	6919B WOODLEY AVE	VAN NUYS	CA	91406	LOS ANGELES	USA	Allergy and Infectious Diseases Research	000	3	3/10/2025	NON-COMPETING CONTINUATION	$1,000,000
														Subtotal = $1,000,000

Issue Date FY: 2024 ( Subtotal = $1,000,000 )
2024	2024	TRACE-ABILITY INC	6919B WOODLEY AVE	VAN NUYS	CA	91406	LOS ANGELES	USA	Allergy and Infectious Diseases Research	000	2	1/12/2024	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$1,000,000
														Subtotal = $1,000,000

Grand Total All Awards = $2,000,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Improving availability of ImmunoPET via automation of radio-synthesis and quality control of antibody-based HIV imaging PET tracers on a single platform.

Award Number: R44AI162202

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 01/15/2024

PERIOD OF PERFORMANCE END DATE: 12/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer